American Liver Foundation

- 1:00 pm Date: May 13th Time: 12 – 1pm ET This session offers a focused, research-driven overview of metabolic dysfunction–associated steatotic liver disease (MASLD) in rural populations, tailored for providers in the primary care setting. It will examine current evidence on screening, diagnosis, and risk stratification, with attention to management within the clinic setting and criteria for escalation or referral to specialists in the context of limited hepatology access.

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC. Earlier this year, proposed changes to the childhood immunization schedule raised concerns about hepatitis B vaccination guidance. This week, a federal judge paused those changes, maintaining current recommendations while the case proceeds. For the liver community, this is especially important.

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC. Breaking news on living donation! On February 26th the Senate Health, Education, Labor, and Pensions (HELP) Committee passed the Living Donor Protection Act (LDPA) out of committee. This is a huge step forward for living organ donation.

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC. Breaking News on Living Donation! On February 26th the Senate Health, Education, Labor and Pensions (HELP) committee will markup the Living Donor Protection Act (LDPA). During the markup Senators will have the opportunity to debate legislation and propose amendments to the bill. This is amazing news for liver patients and is made possible because of your advocacy.

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC. On January 15th American Liver Foundation (ALF) hosted a Congressional briefing entitled, Liver Cancer: Prevalence, Risk Factors and Strategies for Prevention and Treatment to discuss evidence-based strategies for prevention and treatment, as well as legislative solutions aimed at improving access to care for patients.

Leading medical experts and patient advocates discussed prevalence, risk factors and strategies for intervention Leading medical experts and patient advocates came together last week for a Congressional Briefing hosted by American Liver Foundation (ALF) on Liver Cancer: Prevalence, Risk Factors, and Strategies for Prevention and Treatment.

- 8:00 pm Join us for this one-hour live virtual advocacy briefing. We will provide updates around current priorities, review accomplishments from the past year, and provide a preview of 2026. Speakers include: Lorraine Stiehl, CEO, American Liver Foundation Event Date: December 8th, 2025Event Time: 7:00 PM EST Zoom Meeting Link: Please register below to receive the Zoom Link. Details Time: 7:00 pm - 8:00 pm Event Category: Programs

Celebrating Achievements of an Innovative Physician-Scientist, Dedicated Philanthropic Family, Groundbreaking Pediatric Physician and Leading Transplant Surgeon American Liver Foundation’s (ALF) National Legacy Gala will be held Wednesday, Oct. 29 at Gotham Hall in New York City honoring those who have made significant contributions to the liver community.

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC. While the House of Representatives and Senate are still out on August recess, let’s make sure our voices are heard! By sharing your personal experiences, you help lawmakers understand that liver disease isn’t just numbers and statistics; it’s real people, families, and futures.

More than 100 million Americans are living with some form of liver disease. Many don’t even know they have it until it’s too late — when the damage is irreversible and their options are limited. Liver disease is one of the fastest-growing public health crises in our nation, and without urgent action, the toll will keep rising. This is not just about numbers. It’s about you, your neighbors, friends, parents, children- people we love.